Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 in combination with anti-tumor therapies in colorectal cancer
NCT07071714Phase 2Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2025
- Primary completion
- Oct 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CS1002 in colorectal cancer (CRC) (2 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Pathological Complete Response at 7 months and Progression Free Survival at 18 months. Started Jul 2025; status: active, not recruiting.
02
Drugs
CS1002
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07071714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071714.